Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

PURPOSE: This two-part, first-in-human study was initiated in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors (FGFRs) to determine the maximum tolerated dose (MTD), the recommended phase II dose (RP2D), and the schedule, safety, pharmacokinetic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Nogova, Lucia, Sequist, Lecia V., Perez Garcia, Jose Manuel, Andre, Fabrice, Delord, Jean-Pierre, Hidalgo, Manuel, Schellens, Jan H.M., Cassier, Philippe A., Camidge, D. Ross, Schuler, Martin, Vaishampayan, Ulka, Burris, Howard A., Tian, G. Gary, Campone, Mario, Wainberg, Zev A., Lim, Wan-Teck, LoRusso, Patricia, Shapiro, Geoffrey I., Parker, Katie, Chen, Xueying, Choudhury, Somesh, Ringeisen, Francois, Graus-Porta, Diana, Porter, Dale, Isaacs, Randi, Buettner, Reinhard, Wolf, Jürgen
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6865065/
https://ncbi.nlm.nih.gov/pubmed/27870574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.67.2048
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados